Recent Updates
Recently added Catalysts
RCUS Neutral Sentiment

Arcus Biosciences to Participate in the Goldman Sachs 47th Annual Global Healthcare Conference

Key Takeaway: Arcus Biosciences is scheduled to participate in the Goldman Sachs 47th Annual Global Healthcare Conference. This event is a significant gathering for industry leaders and stakeholders. Further details about their presentation or topics of discussion have not been disclosed in the article.
Price reaction · baseline $23.43 (2026-05-22 close) · hit after-hours · clean, no other RCUS news in the window
day 0 close · peak
+3%

Market Sentiment Analysis

BiopharmaWatch Analysis

From our catalyst data and publicly available data · not financial advice
Cash runway
~19 mo
Low dilution risk
Lead asset
Atezolizumab
Phase 2 · Prostate Adenocarcinoma

Full Press Release Details

HAYWARD, Calif.--(BUSINESS WIRE)--Arcus Biosciences (NYSE:RCUS), a clinical-stage, global biopharmaceutical company focused on developing differentiated molecules and combination therapies for patients with cancer and inflammatory and autoimmune diseases, announced that its management team will participate in a fireside chat at the upcoming Goldman Sachs Global Healthcare Conference in Miami Beach, FL. The fireside chat will take place on Tuesday, June 9th, 2026, at 10:40am ET.
A live webcast of the presentation will be available by visiting the “Investors & Media” section of the Arcus Biosciences website atwww.arcusbio.com. A replay will be available following the live event.

About Arcus Biosciences

Arcus Biosciences is a clinical-stage, global biopharmaceutical company focused on developing differentiated molecules for the treatment of cancer and inflammatory and autoimmune diseases. In partnership with industry collaborators, patients and physicians around the world, Arcus is expediting the development of its late-stage portfolio of first- and/or best-in-class medicines against well-characterized biological targets and pathways and studying novel, biology-driven combinations that have the potential to help people with cancer live longer. Founded in 2015, the company has advanced multiple investigational medicines into registrational clinical trials including casdatifan, a HIF-2a inhibitor for clear cell renal cell carcinoma, and quemliclustat, a small-molecule CD73 inhibitor for pancreatic cancer. For more information about Arcus Biosciences’ clinical and preclinical programs, please visitwww.arcusbio.com.
Last updated: May 26, 2026